Screener
Rhythm Pharmaceuticals, Inc. RYTM Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Rhythm Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s debt-to-equity?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported debt-to-equity of 0.9× in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s debt-to-equity decreased by 84.8% year-over-year, from 6× to 0.9×.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s debt-to-equity has grown at a 88.5% compound annual growth rate (CAGR), from 0× to 0.8×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude